Navigation Links
Cardiome And Astellas Announce Initiation Of Patient Enrolment In ACT 5 Trial
Date:10/28/2009

and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements an
'/>"/>
SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Orexigen(R) Therapeutics Presents New Data Showing Weight Loss with Contrave Significantly Improves Important Markers of Cardiometabolic Risk
2. Cardiome Pharma Corp. Announces Final Results of Tender Offer
3. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
4. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
5. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
6. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
7. Cardiome to Hold Conference Call
8. Cardiome Announces Management Transition
9. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
10. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
11. Cardiome Reports First Quarter Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... July 29, 2014 Guests at Napa Valley's ... indulged in a new sleep experience. The top of each ... Peacock Alley. , These expertly crafted, 100% Egyptian cotton ... from a distance, yet upon closer look, words are woven ... relax, sleep and breathe. , Intentional breathing and ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 In its ... offers treatment programs and believes that having family close ... big difference in whether or not the process is ... myths. , “It’s difficult to estimate just how damaging ... Rehabilitation’s CEO Per Wickstrom . “Not only do ...
(Date:7/29/2014)... 29, 2014 Launched in 2012 by ... surpassed 20,000 hangovers earlier this year at its Vegas ... expansion and the publication of research data related to ... practice. , The only licensed medical practice dedicated to ... launched in 2012 and treated thousands of patients within ...
(Date:7/29/2014)... 29, 2014 Ticketability.com has reduced the cost ... been selling at lower prices on the secure website. Customers ... further discount on tickets that are priced lower every day. ... tickets available at Ticketability.com. , Theatergoers know that attending an ... find Phantom of the Opera tickets for sale that are ...
(Date:7/28/2014)... July 29, 2014 Treat skin to a ... Sublime Beauty®. , Today and tomorrow only (while supplies last), ... "The cleanser is ideal for two specific users: , 1) ... unclogged and bacteria free, and , 2) aging skin to ... says Kathy Heshelow, founder of Sublime Beauty®. , Those with ...
Breaking Medicine News(10 mins):Health News:Auberge Du Soleil Offers INTENTIONS™ by Peacock Alley on Guests' Beds Providing a Unique Sleep Experience 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 2Health News:Latest Best Drug Rehabilitation Blog Post Busts 4 Big Addiction Myths 3Health News:Hangover Heaven Surpasses 20,000 Hangovers 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 3Health News:Phantom of the Opera Tickets for Sale: Ticketability.com Delights Customers with Phantom of the Opera Theatre Tickets While Seats Last 2Health News:Clear, Clean Skin With the New Salicylic Wash from Sublime Beauty®; Enlivens Skin, Unclogs Pores 2
... Ten outstanding clinical research projects from institutions around the ... Research Forum Top 10 Clinical Research Achievement Awards. The ... that results from the nation,s investment in clinical research ... hail from Baylor College of Medicine, the Cleveland Clinic ...
... , WEDNESDAY, April 18 (HealthDay News) -- ... adults, risk of being hospitalized for lung and heart ... Harvard School of Public Health researchers compared air-quality data ... 65 and older admitted to 3,000 New England hospitals ...
... 17 (HealthDay News) -- Pregnant women who are overweight ... for pregnancy complications, a new study shows. These women ... normal blood sugar or those with gestational diabetes and normal ... pregnant women who are obese or have gestational diabetes, and ...
... , TUESDAY, April 17 (HealthDay News) -- A new study ... new kind of radiation treatment, in patients with prostate cancer. ... radiation therapy were more likely to suffer from gastrointestinal side ... be any extra benefit for those who got proton therapy. ...
... , TUESDAY, April 17 (HealthDay News) -- Mothers with ... according to a new study. Pennsylvania State University researchers ... the ages of 1 month and 2 years over 7 ... mothers and their infants, quality of sleep. Greater amounts ...
... HealthDay Reporter , TUESDAY, April 17 (HealthDay News) ... cells led to a nearly 50 percent improvement in survival ... that claimed the life of U.S. Sen. Edward Kennedy, a ... about 40 patients with recurrent glioblastoma -- an aggressive brain ...
Cached Medicine News:Health News:Awards celebrate clinical research that can improve health and alleviate suffering 2Health News:Awards celebrate clinical research that can improve health and alleviate suffering 3Health News:More Smog Might Mean More Hospitalizations 2Health News:Overweight Pregnant Women at Higher Risk for Complications 2Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 2Health News:Study Casts Doubt on Value of Pricey Prostate Cancer Therapy 3Health News:Depressed Moms May Hinder Babies' Sleep 2Health News:Brain Tumor Vaccine Shows Promise in Early Trial 2
(Date:7/28/2014)... July 28, 2014 Reportlinker.com announces that ... its catalogue: Portugal Pharmaceuticals and ... http://www.reportlinker.com/p0207141/Portugal-Pharmaceuticals-and-Healthcare-Report-Q3-2014.html Includes 3 ... Faster-than-expected economic growth last quarter has led us ... upwards. As forecast previously, BMI expects ...
(Date:7/28/2014)... Va. , July 28, 2014  Serco ... services, announced the Company has been awarded a ... Support Command (NEMSCOM) and its Deployable Medical Systems.  ... enable medical personnel to provide world-class healthcare to ... operating environment across the globe. The five year ...
(Date:7/28/2014)... 2014  VigeneTech, Inc, in collaboration with BioLegend, ... Analysis Software, an OEM software solution for analysis ... and offers varieties of bead-based multi-analyte immunoassay products ... of VigeneTech,s data analysis software, FCS data files ... reported LEGENDplex™ software is a ...
Breaking Medicine Technology:Portugal Pharmaceuticals and Healthcare Report Q3 2014 2Portugal Pharmaceuticals and Healthcare Report Q3 2014 3Portugal Pharmaceuticals and Healthcare Report Q3 2014 4Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2VigeneTech Releases New Powerful Software for Flow Cytometry Data Analysis 2
... VANCOUVER, Oct. 7 /PRNewswire-FirstCall/ - Burcon NutraScience,Corporation ... and,Supertein(TM) canola protein isolates are GRAS (Generally ... a variety of food and beverage,applications. The ... evaluation by a panel of qualified experts ...
... study of adults, VYVANSE taken once-daily significantly,improved the ... Oct. 7 Shire plc (LSE: SHP,Nasdaq: SHPGY), ... study published in the September issue of the ... Deficit Hyperactivity Disorder (ADHD) symptoms in adults within,the ...
Cached Medicine Technology:Burcon announces GRAS status for Puratein(R) & Supertein(TM) 2Burcon announces GRAS status for Puratein(R) & Supertein(TM) 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 2Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 3Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 4Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 5Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD 6
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: